Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9052294 | 0.93 | BCHE (0.51) | BCHEACHEHTR1ASLC6A4CYP2J2 | |
| SCHEMBL9052166 | 0.91 | SLC18A3 (0.47) | BCHEACHEHTR1ASLC6A4FFAR4 | |
| SCHEMBL9050709 | 0.86 | — | — | |
| SCHEMBL9053139 | 0.83 | HTR2A (0.48) | BCHEACHE | |
| SCHEMBL24093152 | 0.80 | HRH3 (0.50) | SLC6A4FFAR4HRH3SLC18A3 | |
| SCHEMBL9052143 | 0.79 | OPRM1 (0.48) | — | |
| SCHEMBL5915357 | 0.77 | BCHE (0.64) | BCHEACHE | |
| SCHEMBL11798274 | 0.77 | CYP2J2 (0.61) | CYP2J2CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL9252897 | 0.76 | ACHE (0.67) | BCHEACHEHTR1ASLC6A4 | |
| SCHEMBL9254685 | 0.76 | ACHE (0.60) | BCHEACHEHTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996002250-A1 | HALOPERIDOL ANALOGS AND THE USE THEREOF | ACEA PHARMACEUTICALS INC. (US) | 1996-02-01 | — | — | WO | disclosed |